BioTech

Biotech Most Volatile: Marina Biotech (OTCMKTS:MRNA), Onconova Therapeutics (NASDAQ:ONTX), OXiGENE Inc (NASDAQ:OXGN), Oragenics Inc (NYSEMKT:OGEN)

Marina Biotech, Inc. (OTCMKTS:MRNA) illustrated a similar run of events, as it reinvigorated its PR activity in the new year and shot upwards as it received a patent protection for one of its therapies. MRNA is back at $1.38, after it slumped for a while following a temporary peak at $1.70. Marina Biotech, Inc. (OTCMKTS:MRNA) stock performance was 16.67% in last session and finished the day at $1.40. Traded volume was 585,855 million shares in the last session and the average volume of the stock remained 306.41 million shares. The beta of the stock remained 1.72. Marina Biotech, Inc. (OTCMKTS:MRNA) insider ownership is 0.09%.

Onconova Therapeutics (NASDAQ:ONTX) released its earnings data on Monday. The company reported ($0.68) earnings per share for the quarter, beating the analysts’ consensus estimate of ($1.07) by $0.39, AR Network reports. Onconova Therapeutics Inc (NASDAQ:ONTX) dropped -8.71 percent to $7.44 yesterday on volume of 852,175.00 million shares. The intra-day range of the stock was $7.02 to $8.50. Onconova Therapeutics Inc (NASDAQ:ONTX) has a market capitalization of $159.30 million.

OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report year-end 2013 results on Tuesday March 18th, 2014. A conference call and webcast hosted by OXiGENE management will begin at 4:30 pm ET (1:30 p.m. PT).OXiGENE Inc (NASDAQ:OXGN)’s stock on Mar 11, 2014 reported an increase of 17.48% to the closing price of $2.42. Its fifty two weeks range is $1.96 -$4.95. The total market capitalization recorded $27.75 billion. The overall volume in the last trading session was 6,334,713 million shares. In its share capital, OXiGENE Inc (NASDAQ:OXGN) has 2.64 million outstanding shares.

Oragenics, Inc. (NYSEMKT:OGEN)is focused on the discovery, development and commercialization of a range of technologies associated with oral health, antibiotics and other general health benefits. On Tuesday, shares of Oragenics Inc (NYSEMKT:OGEN) dropped -7.65% to close the day at $3.14. Company return on investment (ROI) is -101.90% and its monthly performance is recorded as -7.37%. Oragenics Inc (NYSEMKT:OGEN) quarterly revenue growth is -3.09%.